share_log

JP Morgan Upgrades Mersana Therapeutics to Neutral, Announces $5 Price Target

Moomoo 24/7 ·  Mar 19 05:50

JP Morgan analyst Brian Cheng upgrades Mersana Therapeutics (NASDAQ:MRSN) from Underweight to Neutral and announces $5 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment